Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-Label, Phase Ib/II Study of YL202 in Combination With Anti-tumor Therapy to Evaluate the Safety, Tolerability, and Efficacy in Patients With Advanced Solid Tumors

NCT07169994 is registered in ClinicalTrials.gov with MediLink Therapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07169994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-Label, Phase Ib/II Study of YL202 in Combination With Anti-tumor Therapy to Evaluate the Safety, Tolerability, and Efficacy in Patients With Advanced Solid Tumors
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 2, 2025
Completion date
November 30, 2027
Enrollment
414 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, breast cancer, non small cell lung cancer